文献速递瓣膜病与结构性心脏病

风湿性二尖瓣疾病的基线特征与结局:EURObservational研究项目瓣膜性心脏病II调查

Baseline characteristics and outcomes of rheumatic mitral valve disease: the EURObservational Research Programme Valvular Heart Disease II Survey.
PubMed 文献 · Eur Heart J · 2025-01-01

该国际前瞻性纵向多中心观察研究在222个中心纳入严重原生瓣膜病或既往瓣膜干预患者,其中470例为严重风湿性二尖瓣病、332例有既往风湿性二尖瓣干预。在具有I类推荐干预的患者中仅70%接受了干预,院内总死亡率为1.5%、6个月随访为3.5%。6个月死亡的独立预测因素包括年龄、慢性肺病、就诊时NYHA III-IV级、肝功能障碍和既往心肌梗死。

要点

  • 风湿性二尖瓣病患者对指南I类推荐干预的依从性仅70%。
  • 院内总死亡率1.5%,6个月随访死亡率3.5%。
  • 6个月死亡独立预测因素包括年龄、慢性肺病、NYHA III-IV级、肝功能障碍和既往心梗。

核心结论

  • 风湿性瓣膜病患者对指南推荐干预的总体依从性差,需加强教育以改善这一脆弱患者群体的管理。

研究设计与样本

  • 欧洲心脏病学会瓣膜性心脏病II注册研究为国际前瞻性纵向多中心观察研究,在222个中心开展。
  • 纳入严重原生瓣膜病或既往瓣膜干预患者,随访在6个月时于调查中心或通过电话进行。
  • 分析人群包括470例严重风湿性二尖瓣病患者和332例既往风湿性二尖瓣干预患者。

主要发现

  • 在具有I类推荐干预的风湿性二尖瓣病患者中,仅70%接受了干预。
  • 原生瓣膜病患者对指南推荐的依从性高于既往干预患者。
  • 院内总死亡率为1.5%,6个月随访总死亡率为3.5%。
  • 6个月死亡的独立预测因素为年龄、慢性肺病、就诊时NYHA III-IV级、肝功能障碍和既往心肌梗死。

关键数值与推荐

  • 具有I类推荐干预的风湿性二尖瓣病患者中干预实施比例为70%。
  • 院内总死亡率为1.5%,6个月随访总死亡率为3.5%。

临床怎么用

  • 应提高风湿性二尖瓣病患者对指南I类推荐干预的依从性。
  • 对具有年龄、慢性肺病、NYHA III-IV级、肝功能障碍或既往心肌梗死等风险因素的患者应加强关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Rheumatic heart disease is the commonest acquired cardiovascular disease worldwide. About 20 years have elapsed since the original Euro Heart Survey on valvular heart disease (VHD) was conducted with multiple changes in practice due to advances in treatment techniques. In this study, we aimed to analyse the management of patients with severe native valve disease or those with previous valvular intervention in comparison with existing European Society of Cardiology guidelines. METHODS: The European Society of Cardiology VHD II registry is an international, prospective, longitudinal multicentre, observational study, which was conducted in 222 centres. The registry included patients with severe native VHD or with previous valvular intervention. Follow-up was undertaken at 6 months at the investigating centre or by telephone. RESULTS: Amongst patients recruited in the European Society of Cardiology VHD II registry, 470 had severe rheumatic mitral valve disease and 332 had previous rheumatic mitral valve intervention. Amongst the patients with Class I recommendation for intervention, it was undertaken in only 70%. Adherence to guideline recommendations was more in patients with native VHD than in those with previous intervention. Total mortality was 1.5% in hospital and 3.5% at 6 months follow-up. Independent predictors of death at 6 months were age, chronic pulmonary disease, New York Heart Association Classes III and IV at presentation, liver dysfunction, and previous myocardial infarction. CONCLUSIONS: Compliance with guideline recommendations for intervention is poor overall in patients with rheumatic valve disease. Concerted educational efforts are needed to improve the management of this vulnerable patient cohort.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Abdelhamid M, Abdel Meged AM, Prendergast B, et al. Baseline characteristics and outcomes of rheumatic mitral valve disease: the EURObservational Research Programme Valvular Heart Disease II Survey. Eur Heart J. 2025. PMID: 39932741. doi:10.1093/eurheartj/ehaf050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。